News & Updates
Filter by Specialty:
Show Multimedia Only

Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
byAudrey Abella
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).